ClinicalTrials.gg
RecruitingNCT06007248Updated Nov 19, 2025

Disease Characteristics of IR-CAD: a Case-control Study

An observational study in Coronary Artery Disease, Coronary Artery Stenosis and Coronary Artery Restenosis, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 45 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-11-19.

Sponsored by Peking Union Medical College Hospital · Observational

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
30
Ages
45 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Coronary Artery Disease by Peking Union Medical College Hospital — 5 open to participants now, 5 under way, none of them phase 3. Coronary Artery Disease · Peking Union Medical College Hospital.

Started
2023
with 2 others
Observational
5 of 10
4 open now
Registered
8th of 10
by date

Among the 10 studies in Coronary Artery Disease by Peking Union Medical College Hospital, this one is one of 3 that started in 2023, is one of 5 observational ones, and was the 8th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

5 of the 10 studies in Coronary Artery Disease by Peking Union Medical College Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 45 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Coronary Artery Disease by Peking Union Medical College Hospital, or all of them as a file.
02

Study summary

The present case-control study is designed to investigate the disease characteristics of IR-CAD by comparing the demographics, clinical features, lab results, imaging findings, and prior treatment between 20 patients with IR-CAD and 10 patients with AS-CAD.

Read the detailed description

A special type of coronary artery disease (CAD) has been identified in the investigators' clinical practice, which has completely different clinical features from those of typical atherosclerotic coronary artery disease (AS-CAD). The patients often have sterile inflammatory diseases and/or clinical evidence of inflammation, whose CAD progresses rapidly, recurs frequently, and responds poorly to intensified secondary prevention of AS-CAD, especially after percutaneous coronary intervention (PCI). The investigators name this special type of CAD with inflammation-associated rapidly-progressive coronary artery disease (IR-CAD). Currently, the overall disease characteristics of IR-CAD remain unknown.

The present case-control study is designed to investigate the disease characteristics of IR-CAD by comparing the demographics, clinical features, lab results, imaging findings, and prior treatment between 20 patients with IR-CAD and 10 patients with AS-CAD.

The first 20 patients who were enrolled in the IR-CAD cohort study, which included patients who met the inclusion/exclusion criteria for IR-CAD and received comprehensive treatment, will be enrolled in the case group of the present IR-CAD case-control study. Patients were diagnosed as IR-CAD if they have 1) evidence of rapidly progressive (occurred within 6 months or occurred on immunosuppressive therapy within 12 months of the last coronary revascularization) myocardial ischemia (typical symptoms and non-invasive evidence) despite standard treatment for secondary prevention of AS-CAD; 2) angiographic evidence of new coronary lesions (de novo stenosis or restenosis) considered to be relevant to myocardial ischemia; 3) evidence of inflammation (positive inflammation markers or established diagnosis of inflammatory diseases or use of immunosuppressive therapy). The comprehensive treatment for IR-CAD included: 1) intensified secondary prevention of AS-CAD; 2) immunosuppressive therapy; 3) coronary revascularization; 4) supportive therapies.

Patients who fulfill the inclusion/exclusion criteria for AS-CAD defined by the protocol of the present case-control study will be enrolled in the control group of the present case-control study. Patients will be diagnoses as AS-CAD if they 1) are ≥ 45 but \< 65 years of age; 2) are receiving standard treatment for secondary prevention of AS-CAD after the last PCI which was performed 12±6 months ago; 3) do not have evidence of rapidly progressive (occurred within 6 months or occurred on immunosuppressive therapy within 12 months of the last PCI) myocardial ischemia (typical symptoms and non-invasive evidence); 4) do not have angiographic evidence of new coronary lesions (de novo stenosis or restenosis) considered to be relevant to myocardial ischemia.

Patients in the IR-CAD cohort study underwent examinations after they met the inclusion/exclusion criteria for IR-CAD based on a protocol specifically designed for the clinical management of IR-CAD patients. The results of the above examinations will be used as the examination results of the case group of the present IR-CAD case-control study. While patients in the control group of the present case-control study will undergo similar examinations after enrollment according to the protocol of the present case-control study.

The information regarding the baseline characteristics and the examination results, including demographics, clinical features, lab results, imaging findings, and prior treatment, will be collected and compared between the case group and the control group.

The primary endpoint is the rate of elevated erythrocyte sedimentation rate (ESR).

Eligible patients will be enrolled in the case group and the control group with a 2:1 ratio. The primary endpoint of the present case-control study is elevated erythrocyte sedimentation rate (ESR), which is defined as ESR > 15 mm for male, or ESR > 20 mm for female. In case of normal ESR, prior use of immunosuppressive therapy or prior diagnosis of autoimmune diseases before enrollment is regarded as the equivalent to elevated ESR. Based on currently available data from the IR-CAD cohort study, the rate of elevated ESR in the case group (IR-CAD patients) is 88.9% (8/9). The investigators hypothesize that the rate of elevated ESR in the control group (AS-CAD patients) is 20%. In consequence, 20 patients in the case group and 10 patients in the control group would be required to test the difference of the rate of the primary endpoint between the two groups at a significance level of 0.05 (α = 0.05) with a power of 90% (β = 0.10) and a drop-out rate of 20%.

Continuous variables will be presented as mean ± standard deviation (SD) or median (interquartile range [IQR]) and compared with two-sample t-test or Wilcoxon rank sum test, as appropriate. Categorical data will be demonstrated as n (%) and compared using Chi-square test or Fisher's exact test, as appropriate.

03

Conditions studied

  • Coronary Artery Disease
  • Coronary Artery Stenosis
  • Coronary Artery Restenosis
  • Coronary Artery Disease Progression
  • Inflammation
  • Inflammatory Disease
  • Inflammation Vascular

Keywords

  • Coronary Artery Disease
  • Coronary Revascularization
  • Progression, Disease
  • Inflammation
  • Characteristics Disease
04

Who can participate

Ages eligible
45 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The first 20 patients who were enrolled in the IR-CAD cohort study, which included patients who met the inclusion/exclusion criteria for IR-CAD and received comprehensive treatment, will be enrolled in the case group of the present IR-CAD case-control study.

Patients who fulfill the inclusion/exclusion criteria for AS-CAD defined by the protocol of the present case-control study will be enrolled in the control group of the present case-control study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Case group (IR-CAD patients):

  1. 18 years of age or older, male or female.
  2. Negative results of urine or blood pregnancy test for females with (not or surgically sterile).
  3. Prior history of coronary revascularization (PCI or coronary artery bypass graft [CABG]).
  4. Receiving standard treatment for secondary prevention of AS-CAD after the last coronary revascularization.
  5. Hospitalization due to rapidly-progressive myocardial ischemia:

    • Typical symptoms of angina (Canadian Cardiovascular Society [CCS] III-IV) and non-invasive evidence of myocardial ischemia; and
    • Occurred within 6 months or occurred on therapy within 12 months of the last coronary revascularization.
  6. Angiographic evidence of new coronary lesions (de novo stenosis or restenosis) considered to be relevant to myocardial ischemia.
  7. Evidence of inflammation:

    • At least one of the indexes indicating active inflammation has ever been elevated (ESR, high-sensitivity C-reactive protein [hs-CRP], interleukin [IL]-6, tumor necrosis factor [TNF]-α, ferritin, et al); or
    • Established diagnosis of systemic disease or systemic vasculitis; or
    • Receiving immunosuppressive therapy.

Control group (AS-CAD patients):

  1. ≥ 45 and \< 65 years of age (based on the age distribution of the patients currently enrolled in the IR-CAD cohort study), male or female.
  2. Negative results of urine or blood pregnancy test for females with childbearing potential (not post-menopausal or surgically sterile).
  3. Currently, 12±6 months after the last PCI.
  4. Receiving standard treatment for secondary prevention of AS-CAD after the last PCI.
  5. Coronary angiography and/or optical coherence tomography (OCT) performed during the present hospitalization.
  6. No evidence of rapidly-progressive myocardial ischemia, which is defined as follows:

    • Typical symptoms of angina (Canadian Cardiovascular Society [CCS] III-IV) and non-invasive evidence of myocardial ischemia; and
    • Occurred within 6 months or occurred on immunosuppressive therapy within 12 months of the last PCI.
  7. No angiographic evidence of new coronary lesions (de novo stenosis or restenosis) considered to be relevant to myocardial ischemia.

Exclusion criteria

Exclusion Criteria:

Case group (IR-CAD patients):

  1. Coronary restenosis due to mechanical factors (stent under-expansion, stent mal-apposition, stent rupture, et al).
  2. Other moderate to severe heart diseases (congenital heart disease, valvular heart disease, myocarditis, cardiomyopathy, pericardial diseases, pulmonary hypertension, heart failure, arrhythmia, et al).
  3. Active acute or chronic infection ( [HIV], tuberculosis, et al).
  4. Active (diagnosed within 12 months or with ongoing requirement for treatment).
  5. Vital organ failure.
  6. \< 1 year.
  7. for or intolerance to treatment for secondary prevention of AS-CAD, contrast agents, , agents.
  8. In pregnancy or breast-feeding, or with intention to be pregnant during the study period.
  9. Risk of non-compliance (history of drug addiction or alcohol abuse, et al).
  10. Previous enrollment in this study.
  11. Participation in another study within 30 days.
  12. Involvement in the planning and conduct of this study (applying to investigators, contract research organization staffs, study site staffs, et al).
  13. Any condition, which in the opinion of the investigators, would make it unsuitable for the patient to participate in this study.

Control group (AS-CAD patients):

The same as those for the case group (IR-CAD patients).

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Case Group

    IR-CAD patients (from the IR-CAD cohort study)

    Diagnostic Test: Protocol-defined Examinations

  • Control Group

    AS-CAD patients

    Diagnostic Test: Protocol-defined Examinations

Interventions

  • Diagnostic testProtocol-defined Examinations

    Lab tests (blood and urine and stool routine tests, hepatic and renal and thyroid function tests, tests for metabolic markers, tests for cardiac biomarkers, thrombosis-related tests, rheumatology tests, tests for inflammation markers), electrocardiography, echocardiography, Birmingham Vasculitis Activity Score (BVAS-3), 6-minute walk test, 1-minute squat test, vascular ultrasound, fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT), coronary angiography, optical coherence tomography (OCT), tests for exploratory biomarkers.

06

What researchers measure

Primary outcomes

  1. Elevated erythrocyte sedimentation rate (ESR)

    Percentage of patients with elevated ESR (\> 15 mm for male or \> 20 mm for female). In case of normal ESR, prior use of immunosuppressive therapy or prior diagnosis of autoimmune diseases before enrollment is regarded as the equivalent to elevated ESR.

    Time frame: From the last coronary revascularization up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

Secondary outcomes

  1. Age

    Age in years.

    Time frame: On the day of enrollment.

  2. Female sex

    Percentage of patients with female sex.

    Time frame: On the day of enrollment.

  3. Yellow race

    Percentage of patients with yellow race.

    Time frame: On the day of enrollment.

  4. Acute coronary syndrome (ACS)

    Percentage of patients admitted due to ACS for the index hospitalization.

    Time frame: On the day of enrollment.

  5. Chronic coronary syndrome (CCS).

    Percentage of patients admitted due to CCS for the index hospitalization.

    Time frame: On the day of enrollment.

  6. Hypertension

    Percentage of patients with prior history of hypertension.

    Time frame: On the day of enrollment.

  7. Dyslipidemia

    Percentage of patients with prior history of dyslipidemia.

    Time frame: On the day of enrollment.

  8. Diabetes

    Percentage of patients with prior history of diabetes.

    Time frame: On the day of enrollment.

  9. Smoking

    Percentage of patients with prior history of smoking.

    Time frame: On the day of enrollment.

  10. Old myocardial infarction (OMI)

    Percentage of patients with prior history of OMI.

    Time frame: On the day of enrollment.

  11. Percutaneous coronary intervention (PCI)

    Percentage of patients with prior history of PCI.

    Time frame: On the day of enrollment.

  12. Coronary artery bypass graft (CABG)

    Percentage of patients with prior history of CABG.

    Time frame: On the day of enrollment.

  13. Number of prior coronary revascularization

    Number of prior coronary revascularization

    Time frame: On the day of enrollment.

  14. Blood pressure

    Measurement of blood pressure.

    Time frame: On the day of enrollment.

  15. Heart rate

    Measurement of heart rate.

    Time frame: On the day of enrollment.

  16. Body weight

    Measurement of body weight.

    Time frame: On the day of enrollment.

  17. Height

    Measurement of height.

    Time frame: On the day of enrollment.

  18. Body mass index (BMI)

    BMI = Body weight \[kg\] / (Height \[m\])\^2

    Time frame: On the day of enrollment.

  19. Antithrombotic agents

    Percentage of patients on antithrombotic agents.

    Time frame: On the day of enrollment.

  20. β-blockers

    Percentage of patients on β-blockers.

    Time frame: On the day of enrollment.

  21. Blood pressure-lowering agents

    Percentage of patients on blood pressure-lowering agents.

    Time frame: On the day of enrollment.

  22. Lipid-lowering agents

    Percentage of patients on lipid-lowering agents.

    Time frame: On the day of enrollment.

  23. Hypoglycemic agents

    Percentage of patients on hypoglycemic agents.

    Time frame: On the day of enrollment.

  24. Glucocorticoids

    Percentage of patients on glucocorticoids.

    Time frame: On the day of enrollment.

  25. Immunosuppressive agents

    Percentage of patients on immunosuppressive agents.

    Time frame: On the day of enrollment.

  26. Other immunosuppressive therapy

    Percentage of patients on other immunosuppressive therapy.

    Time frame: On the day of enrollment.

  27. Major adverse cardiovascular events (MACE)

    Percentage of patients with death, or Q wave myocardial infarction, or unplanned myocardial ischemia-driven coronary revascularization (PCI or CABG), or unplanned myocardial ischemia-driven hospitalization.

    Time frame: From the last coronary revascularization up to the day of enrollment.

  28. Target vessel related major adverse cardiovascular events (TV-MACE)

    Percentage of patients with cardiovascular death, or target vessel related Q wave myocardial infarction, or target vessel related unplanned myocardial ischemia-driven coronary revascularization (PCI or CABG), or target vessel related unplanned myocardial ischemia-driven hospitalization.

    Time frame: From the last coronary revascularization up to the day of enrollment.

  29. Hemoglobin

    Test result of hemoglobin.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  30. Red blood cell

    Test result of red blood cell count.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  31. White blood cell

    Test result of white blood cell count.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  32. Platelet

    Test result of platelet count

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  33. Alanine aminotransferase (ALT)

    Test result of ALT.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  34. Aspartate aminotransferase (AST)

    Test result of AST.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  35. Gamma-glutamyl transferase (GGT)

    Test result of GGT.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  36. Alkaline phosphatase (ALP)

    Test result of ALP.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  37. Lactate dehydrogenase (LDH)

    Test result of LDH.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  38. Total bilirubin (T-Bil)

    Test result of T-Bil.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  39. Direct bilirubin (D-Bil)

    Test result of D-Bil.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  40. Albumin

    Test result of Albumin

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  41. Creatinine

    Test result of creatinine.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  42. Blood urea nitrogen (BUN)

    Test result of BUN.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  43. Triiodothyronine (T3)

    Test result of T3.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  44. Thyroxine (T4)

    Test result of T4.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  45. Free triiodothyronine (FT3)

    Test result of FT3.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  46. Free thyroxine (FT4)

    Test result of FT4.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  47. Thyroid-stimulating hormone (TSH)

    Test result of TSH.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  48. Total cholesterol (TC)

    Test result of TC.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  49. Low-density lipoprotein cholesterol (LDL-C)

    Test result of LDL-C.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  50. High-density lipoprotein cholesterol (HDL-C)

    Test result of HDL-C.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  51. Triglyceride (TG)

    Test result of TG.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  52. Apolipoprotein A (ApoA)

    Test result of ApoA.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  53. Apolipoprotein B (ApoB)

    Test result of ApoB.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  54. Lipoprotein (a) (Lp[a])

    Test result of Lp(a).

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  55. Fasting blood glucose (FBG)

    Test result of FBG.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  56. Hemoglobin A1c (HbA1c).

    Test result of HbA1c.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  57. Cardiac troponin I (cTnI)

    Test result of cTnI.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  58. Creatine kinase-myocardial band (CK-MB)

    Test result of CK-MB.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  59. Creatine kinase (CK)

    Test result of CK.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  60. B-type natriuretic peptide (BNP)

    Test result of BNP.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  61. N-terminal pro-B-type natriuretic peptide (NT-proBNP).

    Test result of NT-proBNP.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  62. Lupus anticoagulant

    Test result of lupus anticoagulant.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  63. Antiphospholipid antibody

    Test result of antiphospholipid antibody.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  64. Anti-phosphatidylserine antibody

    Test result of anti-phosphatidylserine antibody.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  65. Anti-prothrombin antibody

    Test result of anti-prothrombin antibody.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  66. Protein S

    Test result of Protein S.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  67. Protein C

    Test result of Protein C.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  68. Activated protein C resistance (APC-R)

    Test result of APC-R.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  69. Anti-thrombin III

    Test result of anti-thrombin III.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  70. Maximum platelet aggregation (MPA)

    Test result of MPA.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  71. Anti-nuclear antibody (ANA)

    Test result of ANA.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  72. Anti-neutrophil cytoplasmic antibody (ANCA)

    Test result of ANCA.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  73. Anti-endothelial cell antibody (AECA)

    Test result of AECA.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  74. Rheumatoid factor (RF)

    Test result of RF.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  75. Anti-cyclic citrullinated peptide (Anti-CCP)

    Test result of Anti-CCP.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  76. Immunoglobulin

    Test result of immunoglobulin.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  77. Complement

    Test result of complement.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  78. Erythrocyte sedimentation rate (ESR)

    Test result of ESR.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  79. High-sensitivity C-reactive protein (hs-CRP)

    Test result of hs-CRP.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  80. Interleukin (IL)-6

    Test result of IL-6.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  81. Tumor necrosis factor (TNF)-α.

    Test result of TNF-α.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  82. Pathological Q waves

    Percentage of patients with pathological Q wave.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  83. Dynamic ST-T changes

    Percentage of patients with dynamic ST-T changes.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  84. Segmental wall motion abnormality

    Percentage of patients with segmental wall motion abnormality.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  85. Left atrial diameter (LAD)

    Measurement of LAD.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  86. Left ventricular end-systolic diameter (LVESD)

    Measurement of LVESD.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  87. Left ventricular end-diastolic diameter (LVEDD)

    Measurement of LVEDD.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  88. Left ventricular ejection fraction (LVEF)

    Measurement of LVEF.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  89. Birmingham Vasculitis Activity Score (BVAS)

    Result of BVAS (version 3) assessment.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  90. Walking distance in 6 minutes

    Result of 6-minute walk test (6MWT).

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  91. Number of squats in 1 minute

    Result of 1-minute squatting test (1MST).

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  92. Temporal artery stenosis

    Percentage of patients with ≥ 50% diameter stenosis in either temporal artery on vascular ultrasound.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  93. Carotid artery stenosis

    Percentage of patients with ≥ 50% diameter stenosis in either carotid artery on vascular ultrasound.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  94. Vertebral artery stenosis

    Percentage of patients with ≥ 50% diameter stenosis in either vertebral artery on vascular ultrasound.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  95. Subclavian artery stenosis

    Percentage of patients with ≥ 50% diameter stenosis in either subclavian artery on vascular ultrasound.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  96. Iliac artery stenosis

    Percentage of patients with ≥ 50% diameter stenosis in either Iliac artery on vascular ultrasound.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  97. Upper extremity artery stenosis

    Percentage of patients with ≥ 50% diameter stenosis in either upper extremity artery on vascular ultrasound.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  98. Lower extremity artery stenosis

    Percentage of patients with ≥ 50% diameter stenosis in either lower extremity artery on vascular ultrasound.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  99. Abdominal aorta stenosis

    Percentage of patients with ≥ 50% diameter stenosis in abdominal aorta on vascular ultrasound.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  100. Celiac trunk stenosis

    Percentage of patients with ≥ 50% diameter stenosis in celiac trunk on vascular ultrasound.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  101. Superior mesenteric artery stenosis

    Percentage of patients with ≥ 50% diameter stenosis in superior mesenteric artery on vascular ultrasound.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  102. Renal artery stenosis

    Percentage of patients with ≥ 50% diameter stenosis in either renal artery on vascular ultrasound.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  103. SYNTAX score

    Result of SYNTAX score assessment based on coronary angiogram.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  104. Number of vessel segments with coronary lesions.

    Number of vessel segments with ≥ 50% diameter stenosis on coronary angiogram.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  105. Target lesion minimal lumen area (TL-MLA)

    Measurement of the minimum lumen area of the target lesion on optical coherence tomography (OCT).

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  106. Target lesion percent area stenosis (TL-%AS)

    Measurement of percent area stenosis (% AS) of target lesion = { \[ ( proximal RLA + distal RLA ) - (MLA × 2) \] / ( proximal RLA + distal RLA ) } × 100% in the cross-section with the MLA of the target lesion on optical coherence tomography (OCT). RLA = reference lumen area; MLA = minimum lumen area; % AS = percent area stenosis.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

Other outcomes

  1. Maximum standardized uptake value (SUVmax)

    The mean of SUVmax of each major coronary artery on fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography (PET/CT).

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  2. RNA sequencing

    Test result of RNA sequencing.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  3. Proteomics

    Test result of proteomics.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

  4. Metabolomics

    Test result of metabolomics.

    Time frame: From the index hospital admission up to 2 weeks of enrollment, but before the initiation of comprehensive treatment for patients with IR-CAD.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020 Jan 14;41(3):407-477. doi: 10.1093/eurheartj/ehz425. No abstract available. PubMed 31504439 ↗
  • Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimsky P; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018 Jan 7;39(2):119-177. doi: 10.1093/eurheartj/ehx393. No abstract available. PubMed 28886621 ↗
  • Collet JP, Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Juni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021 Apr 7;42(14):1289-1367. doi: 10.1093/eurheartj/ehaa575. No abstract available. PubMed 32860058 ↗
  • Neumann FJ, Sousa-Uva M. 'Ten commandments' for the 2018 ESC/EACTS Guidelines on Myocardial Revascularization. Eur Heart J. 2019 Jan 7;40(2):79-80. doi: 10.1093/eurheartj/ehy855. No abstract available. PubMed 30615155 ↗
  • Fernandez DM, Giannarelli C. Immune cell profiling in atherosclerosis: role in research and precision medicine. Nat Rev Cardiol. 2022 Jan;19(1):43-58. doi: 10.1038/s41569-021-00589-2. Epub 2021 Jul 15. PubMed 34267377 ↗
  • Deroissart J, Porsch F, Koller T, Binder CJ. Anti-inflammatory and Immunomodulatory Therapies in Atherosclerosis. Handb Exp Pharmacol. 2022;270:359-404. doi: 10.1007/164_2021_505. PubMed 34251531 ↗
  • Engelen SE, Robinson AJB, Zurke YX, Monaco C. Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed? Nat Rev Cardiol. 2022 Aug;19(8):522-542. doi: 10.1038/s41569-021-00668-4. Epub 2022 Jan 31. PubMed 35102320 ↗
  • Tucker B, Vaidya K, Cochran BJ, Patel S. Inflammation during Percutaneous Coronary Intervention-Prognostic Value, Mechanisms and Therapeutic Targets. Cells. 2021 Jun 4;10(6):1391. doi: 10.3390/cells10061391. PubMed 34199975 ↗
  • Kalkman DN, Aquino M, Claessen BE, Baber U, Guedeney P, Sorrentino S, Vogel B, de Winter RJ, Sweeny J, Kovacic JC, Shah S, Vijay P, Barman N, Kini A, Sharma S, Dangas GD, Mehran R. Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions. Eur Heart J. 2018 Dec 7;39(46):4101-4108. doi: 10.1093/eurheartj/ehy633. PubMed 30358832 ↗
  • Guedeney P, Claessen BE, Kalkman DN, Aquino M, Sorrentino S, Giustino G, Farhan S, Vogel B, Sartori S, Montalescot G, Sweeny J, Kovacic JC, Krishnan P, Barman N, Dangas G, Kini A, Baber U, Sharma S, Mehran R. Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention. J Am Coll Cardiol. 2019 May 21;73(19):2401-2409. doi: 10.1016/j.jacc.2019.01.077. PubMed 31097159 ↗
  • Takahashi N, Dohi T, Endo H, Funamizu T, Wada H, Doi S, Kato Y, Ogita M, Okai I, Iwata H, Okazaki S, Isoda K, Miyauchi K, Shimada K. Residual Inflammation Indicated by High-Sensitivity C-Reactive Protein Predicts Worse Long-Term Clinical Outcomes in Japanese Patients after Percutaneous Coronary Intervention. J Clin Med. 2020 Apr 6;9(4):1033. doi: 10.3390/jcm9041033. PubMed 32268533 ↗
  • Kikuchi S, Okada K, Hibi K, Maejima N, Yabu N, Uchida K, Tamura K, Kimura K. Coronary arteritis: a case series. Eur Heart J Case Rep. 2020 Feb 17;4(2):1-6. doi: 10.1093/ehjcr/ytaa011. eCollection 2020 Apr. PubMed 32352046 ↗
  • Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, van den Brand M, Van Dyck N, Russell ME, Mohr FW, Serruys PW. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005 Aug;1(2):219-27. No abstract available. PubMed 19758907 ↗
  • Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; ESC Scientific Document Group. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2019 Jan 14;40(3):237-269. doi: 10.1093/eurheartj/ehy462. No abstract available. PubMed 30165617 ↗
  • Braunwald E. Unstable angina. A classification. Circulation. 1989 Aug;80(2):410-4. doi: 10.1161/01.cir.80.2.410. No abstract available. PubMed 2752565 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Sep 2026, 34 months after the start.

Of 637 non-industry observational studies under Coronary Artery Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 122. This study's planned 34 months is below that.

Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2023
First posted
Aug 23, 2023
StartActual
Nov 2, 2023
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
Nov 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06007248
Responsible party
LiuZhenyu (Professor, Peking Union Medical College Hospital) — Principal investigator
First posted
Aug 23, 2023
Start date
Nov 2, 2023
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Nov 19, 2025

Study contacts

Zhenyu Liu, M.D.
Contact
Pumch_lzy@163.com
+861069155068
Zhenyu Liu, M.D.
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion